In conclusion, GLP-1 RAs reduce the risk of MACE versus placebo in patients with T2DM and obesity, whereas SGLT-2 inhibitors tend to be statistically favorable but do not show a significant difference. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.